Shreya Kanodia

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. doi request reprint Peptide-based vaccines for cancer: realizing their potential
    Shreya Kanodia
    Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, NRT 7517, University of Southern California, 1450 Biggy Street, Los Angeles, CA 90033, USA
    Expert Rev Vaccines 7:1533-45. 2008
  2. pmc Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression
    Shreya Kanodia
    Department of Molecular Microbiology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA
    Cancer Res 70:3955-64. 2010
  3. pmc Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages
    Andrew Gray
    Department of Molecular Microbiology and Immunology, University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States
    Vaccine 27:G52-9. 2009
  4. ncbi request reprint Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions
    Shreya Kanodia
    Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
    Int J Cancer 122:247-59. 2008

Collaborators

Detail Information

Publications4

  1. doi request reprint Peptide-based vaccines for cancer: realizing their potential
    Shreya Kanodia
    Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, NRT 7517, University of Southern California, 1450 Biggy Street, Los Angeles, CA 90033, USA
    Expert Rev Vaccines 7:1533-45. 2008
    ..This review will describe the advances in the identification, design and delivery of peptides, the challenges to successful immunotherapy and will discuss potential options for the future...
  2. pmc Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression
    Shreya Kanodia
    Department of Molecular Microbiology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA
    Cancer Res 70:3955-64. 2010
    ..These data establish the safety of Ad-LIGHT as a therapeutic intervention in preclinical studies and suggest that patients with HPV16(+) tumors may benefit from combined immunotherapy with LIGHT and antigen-specific vaccination...
  3. pmc Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages
    Andrew Gray
    Department of Molecular Microbiology and Immunology, University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, CA 90033, United States
    Vaccine 27:G52-9. 2009
    ..These results indicate that prostate cancer immunotherapy trials will be more successful if conducted in patients with less advanced disease...
  4. ncbi request reprint Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions
    Shreya Kanodia
    Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
    Int J Cancer 122:247-59. 2008
    ..Progress in peptide-based vaccines, DNA-based vaccines, viral/bacterial vector-based vaccines, immune response modifiers, photodynamic therapy and T cell receptor based therapy for HPV will be discussed...